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Epidemiology and Clinical Characteristics of Clostridium difficile 
Infection in a Korean Tertiary Hospital
In order to investigate the incidence, clinical and microbiologic characteristics of 
Clostridium difficile infection (CDI) in Korea, a prospective observational study was 
performed. From September 2008 through January 2010, all patients whose stool was 
tested for toxin assay A&B and/or C. difficile culture were studied for clinical 
characteristics. Toxin types of the isolates from stool were tested. The mean incidence of 
CDI per 100,000 patient-days was 71.6 by month (range, 52.5-114.0), and the ratio of 
CDI to antibiotic-associated diarrhea was 0.23. Among 200 CDI patients, 37.5% (75/200) 
was severe CDI based on severity score. Clinical outcome of 189 CDI was as followed; 
25.9% (49/189) improved without treatment, 84.3% (118/140) achieved clinical cure and 
attributed mortality was 0.7% (1/140) with the treatment. Recurrence rate was 21.4% 
(30/140) and cure without recurrence was 66.4% (93/140). The most common type of 
toxin was toxin A-positive/toxin B-positive strain (77.5%), toxin A-negative/toxin 
B-positive strains or binary toxin-producing strains comprised 15.4% or 7.1%, respectively. 
In conclusion, the incidence of CDI in Korea is a little higher than other reports during the 
non-epidemic setting. We expect that the change of epidemiology and clinical severity in 
CDI can be evaluated based on these results. 
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INTRODUCTION
Clostridium difficile infection (CDI) has been a common health-
care-associated infection since the first recognition as a cause 
of pseudomembranous colitis in 1974. Emergence of hypervir-
ulent strains changed clinical characteristics and epidemiology 
of CDI in North America (1). North American pulsed-field type 
1 (BI/NAP1/027) is the most common hypervirulent strain and 
have influenced five-fold increase in incidence and mortality of 
CDI (2). Nevertheless, there are few data about epidemiology in-
cluding prevalence and disease course of CDI in Korea, although 
several retrospective clinical and microbiologic data were pub-
lished (3, 4). 
  This is an observational study to investigate the incidence of 
CDI and distribution of toxigenic C. difficile strains in Korea. We 
also observed demographic, clinical characteristics and treat-
ment outcome of CDI as a baseline data for further study. 
MATERIALS AND METHODS
Design of study
This study was conducted at Hanyang University Hospital, a 900-
bed tertiary care facility located in Seoul, Korea. From Septem-
ber 2008 through January 2010, all patients whose stools were 
tested for toxin assay A&B and C. difficile culture were included 
in the study. Clinical characteristics of the patients were observed 
prospectively, and isolates from the patients were collected for 
further study. 
Definition 
Diarrhea was defined as unformed stools more than 3 times per 
day on consecutive days or 6 times within 36 hr. Antibiotic-as-
sociated diarrhea (AAD) was defined when patient had diarrhea 
and there was no reason for diarrhea except antibiotics use (5). 
We diagnosed CDI when the C. difficile isolates from stool cul-
ture showed positive toxin genes (tcdA, tcdB, cdtA, or cdtB) by 
multiplex PCR, positive results in toxin assay A&B with commer-
cial kit (VIDAS
® C. difficile Toxin A & B; BioMerieux SA, Marcy 
l’Etoile, France), and/or pseudomembrane on endoscopy or 
histology in patients with AAD.
  The CDI patient who developed diarrhea at least 72 hr after 
hospitalization or within the 2 months from last discharge when 
the patient did not reside in healthcare facilities was considered 
as Healthcare-associated CDI (HA-CDI). If the case did not meet 
the definition of HA-CDI, we considered it as community-onset 
CDI (CO-CDI) (6). Patients with C. difficile containing positive 
toxin genes in stool or positive results of toxin assay A&B but 
whose stool characters did not meet the criteria of diarrhea was Kim J, et al.  •  Status of Clostridium difficile Infection in Korea
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considered as toxigenic carrier. Patients with C. difficile without 
toxin genes in stool were non-toxigenic carrier.
Collection of data
Age, sex, length of stay in hospital, operation history and medi-
cation history within 2 months, and underlying disease includ-
ing Charlson’s score were investigated as demographic and clin-
ical data. Instillation of catheter, use and amounts of antibiotics, 
probiotics, proton pump inhibitor, H2 blocker, steroid, or che-
motherapy, and recent operation within 2 months were studied 
as a risk factor of CDI (7). Amounts of antibiotics administered 
were expressed as the number of defined daily dose (DDD), which 
means the total amount of antibiotic divided by the DDD (8). 
We observed whether antibiotics was continued or discontin-
ued after diagnosis of CDI. 
  White blood cell (WBC) count, albumin and C-reactive pro-
tein (CRP) level were tested within 24 hr of enrollment to assess 
disease severity. Age  > 60 yr, temperature  > 38.3°C, albumin level 
< 2.5 mg/dL, or WBC count  > 15,000 cells/µL got 1 point each 
and the pseudomembrane confirmed by endoscopy or admis-
sion in the intensive care unit got 2 points each. Sum of points 
was assessed as severity score of CDI and considered to have 
severe CDI with  ≥ 2 points (9). Stool character and frequency, 
abdominal pain and tenderness, and laboratory findings were 
observed within 24 hr after inclusion. 
  Clinical cure was defined as resolution of diarrhea within the 
treatment period. Clinical failure was defined as the need for treat-
ment change for the resolution of diarrhea. Resolution of diar-
rhea required conversion to two or fewer semiformed or formed 
stools/day (10). Recurrence was defined as growth of C. difficile 
with toxin genes, positive toxin assay A&B, or pseudomembrane 
on endoscopy with resurgence of symptoms after cessation of 
treatment, at least 10 days after the first episode (11). Global cure 
was defined as patients who were cured clinically and did not 
have a recurrence.
Isolates of C. difficile
Stool specimens were grown anaerobically on C. difficile Moxa-
lactam-Norfloxacin-Taurocholate agar (CDMN-TA, Oxoid Ltd., 
Cambridge, UK) supplemented with 7% horse blood after alco-
hol shock (12). Colonies of C. difficile were identified by Rapid 
ID 32A (BioMerieux SA, Marcy l’Etoile, France).
Multiplex PCR for toxin gene detection
With template DNA, multiplex PCR was performed as described 
elsewhere with minor modification (13). Gels were run under 
standard condition on 1.0% agarose for 25 min and stained with 
ethidium bromide for visualization. The size of toxin gene tcdA, 
tcdB, cdtA, and cdtB was 629, 410, 221, and 262 bp, respectively.
Toxinotyping for tcdA gene 
Positive results of tcdA by multiplex PCR meant intact A2 frag-
ment of C. difficile, which did not code for production of A toxin. 
To confirm the production of A toxin in organism, toxinotyping 
for A3 PCR fragment of C. difficile was performed as described 
elsewhere (14). After amplication and subsequent digestion of 
A3 PCR product with restriction enzyme EcoR I, digests were  
visualized on 1.5% agarose gel. According to the type of restric-
tion patterns, we figured out whether isolates had toxin A-pro-
ducing gene or not. 
Statistical methods
SPSS version 13.0 for Windows (SPSS, Chicago, IL, USA) was 
used for statistical analysis. Categorical variables were analyzed 
by Pearon’s chi-square test or Fisher’s exact test. Continuous 
variables were analyzed by independent t-test or Mann-Whit-
ney U-test. A P value of  < 0.05 by two-tailed test was considered 
statistically significant.
Ethics statement
This study was approved by the institutional review board of 
Hanyang University Hospital (HYUH IRB 2010-R-12). Informed 
consent was waived by the board.
RESULTS
During the study period, 200 cases were diagnosed as CDI and 
215 isolates were cultured from stool. In brief, 151 cases were 
Table 1. The composition of Clostridium difficile infection according to diagnostic method 
Toxin genes*
Toxin A&B assay
Subtotal
Positive Negative Not performed
Positive results Image PMC
Other than PMC
Not performed
Subtotal
  15
  15
  71
101
  1
10
39
50
0
0
0
0
  16
  25
110
151
Negative results or 
   not performed
Image PMC
Other than PMC
Not performed
Subtotal
    5
    8
  25
  38
  8
   1
†
  0
  9
2
0
0
2
  15
    9
  25
  49
Total 139 59 2 200
*tcdA, tcdB, cdtA, or cdtB; 
†One CDI patient was confirmed by histologic finding. PMC, pseudomembranous colitis.Kim J, et al.  •  Status of Clostridium difficile Infection in Korea
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CDI with isolation of toxin-producing C. difficile from stool, 49 
were diagnosed by non-culture method, 18 were toxigenic car-
rier and 46 were non-toxigenic carrier (Table 1). For the acqui-
sition of CDI, 11 (5.5%) were CO-CDI and 189 (94.5%) were HA-
CDI. 
Incidence of CDI and AAD 
Incidence was reckoned from Feb 2009 to Jan 2010 because we 
set up the standard culture method on Jan 2009. 
  Total number of AAD was 769 during 1 yr. The mean number 
of AAD by month was 64 (range, 56-76). The mean incidence of 
AAD per 100,000 patient-days and 10,000 admissions by month 
was 313.3 and 326.6, respectively (range, 268.7-378.8 and 278.9-
400). During the same period, total number of CDI was 176. The 
mean number of CDI by month was 15 (range, 11-24). The mean 
incidence of CDI per 100,000 patient-days and 10,000 admissions 
by month were 71.6 and 64.9, respectively (range, 52.5-114.0 
and 45.0-109.6) (Fig. 1). The ratio of CDI to AAD was 0.23.
Distribution of toxigenic C. difficile isolates
The distribution of toxigenic C. difficile strain was classified by 
clinical diagnosis in Table 2. Among 169 toxin-producing isolates, 
the most common type was tcdA-positive tcdB-positive cdtA/B-
negative strain (A
+B
+CDT
-) (131/169, 77.5%). Twenty-six iso-
lates (15.4%) were tcdA-negative tcdB-positive cdtA/B-negative 
strain (A
-B
+CDT
-), and tcdA-positive tcdB-positive cdtA/B-pos-
itive strain (A
+B
+CDT
+) comprised 7.1% (12/169). Distribution 
of toxigenic isolates did not show a difference among HA-CDI, 
CO-CDI and toxigenic carrier (P = 0.929).
Clinical characteristics
Demographic data, previous medication history, and clinical 
and laboratory characteristics of CDI were presented in Table 3. 
Medication history was obtained from 187 CDI because record 
of antibiotics prescription was not available in 9 CO-CDI and 4 
HA-CDI cases. The most common antibiotics used previously 
were extended-spectrum cephalosporins (106, 56.7%), followed 
by respiratory fluoroquinolone (67, 35.8%) and then beta-lac-
tam/beta-lactamase inhibitor (61, 32.6%). There was no history 
of antibiotic use in 2 CO-CDI and 3 HA-CDI cases.
  Severity score of CDI was 1.55 ± 1.337 (mean ± S.D.), and 37.5% 
(75/200) was severe CDI based on severity score (score ≥ 2). Of 
6 factors of severity score, age (64%) was the most common con-
tributing factor for severe CDI.
  Loose to watery character of stool was more common than 
mucoid stool: 155 (77.5%) vs 45 (22.5%). Number of stool pas-
sage more than 10 times per day was observed in 35 CDI (17.5%).
Clinical course and outcome of CDI 
Among 200 CDI, 5 were lost before or during treatment and 6 
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Fig. 1. The number of AAD patients and CDI patients is shown by bars and the incidence of CDI patients per 100,000 patient days by line with italic number. AAD, antibiotic as-
sociated diarrhea; CDI, Clostridium difficile infection; Pt*d, patient-day.
Table 2. Distribution of toxigenic C. difficile according to clinical diagnosis
Genotypes HA-CDI CO-CDI
Toxigenic  
 carrier
  Total (%)
A
+B
+CDT
+   11 0   1 12 (7.1)
A
+B
+CDT
- 110 7 14 131 (77.5)
A
-B
+CDT
-   22 1   3   26 (15.4)
Total  143 8 18   169 (100.0)
*During the study period 46 non-toxigenic C. difficile were isolated from AAD patients 
(46/215, 21.4%). A, tcdA; B, tcdB; CDT, cdtA/B; HA-CDI, healthcare-associated Clos-
tridium difficile infection; CO-CDI, community onset C. difficile infection; AAD, antibi-
otic associated diarrhea.Kim J, et al.  •  Status of Clostridium difficile Infection in Korea
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expired due to underlying disease before treatment, therefore 
clinical course of 189 were observed. Diarrhea stopped without 
treatment in 49 cases (49/189, 25.9%). Self-remitting 49 CDI were 
observed through Jan 2011 at their follow-up clinic or admission 
and mean follow-up period were 281 days (range, 12-712). Among 
49 CDI, 4 cases (8%) re-experienced diarrhea during observa-
tion period with positive toxin assay A&B, and their mean inter-
val between diarrheal episodes were 147 days (range, 60-207). 
Of 140 treated for CDI, 118 (84.3%) were clinical cure, 13 (9.3%) 
showed clinical failure, and 9 (6.4%) expired. However, only 1 of 
9 patients died because of CDI, and attributed mortality was as 
low as 0.7% (1/140). Thirty cases recurred after the end of treat-
ment, and mean recurrence interval was 35 days (range, 12-90). 
Recurrence rate was 21.4%. Of 30 recurred cases, 25 was from 
clinical cure group, therefore, global cure rate was 66.4% (93/140). 
  According to the number of CDI episode, 118 cases (84.3%) 
were treated for the first episode, 17 (12.1%) for the second, 4 
(2.9%) for the third, and 1 (0.7%) for the fourth. Comparing be-
tween the first treatment and retreatment groups, either clinical 
outcome or recurrence rate showed no significant difference (P 
for trend = 0.958, P = 0.256, respectively). 
  For the treatment of CDI, 123 (87.9%) were treated with met-
ronidazole and 17 (12.1%) with vancomycin. Comparing between 
cases treated with each drug, there was no significant difference 
in clinical outcome: clinical cure, failure, mortality and attribut-
ed mortality of metronidazole and vancomycin, 83.7%, 10.6%, 
5.7% and 0% vs 88.2%, 0%, 11.8% and 5.9%, respectively (P for 
trend = 0.912) (Table 4). 
DISCUSSION
This is the first study prospectively observing the prevalence and 
clinical characteristics of CDI in Korea. We expect that a change 
of incidence or disease severity in further years could be stud-
ied based on these results, because 2 BI/NAP1/027 strains were 
isolated in Korea (15), and 5 more strains were discovered in 
this study (data not shown).
  The incidence of CDI in Korea was reported variously from 
8.82 to 71.71 cases per 10,000 patient admissions during the same 
period (3, 16). According to each study definition, 34.4% of CDI 
were severe cases, 47.7% of CDI patient complained of 5-7 loose 
stools/day, and 2.6 to 9.7% of CDI resolved diarrhea without treat-
ment (3, 17). Relapse rate was also variable from 7% to 38.3% 
(17, 18). Attributable mortality was estimated 0.4%-1.3% in HA-
Table 3. Demographic and clinical characteristics of the cases of Clostridium difficile 
infection
Parameters
No.(%)/mean (SD) 
(n = 200)
Sex Male 108 (54.0)
Age (yr)    64.0 (15.58)
Underlying disease Malignancy
CVA
DM
  65 (32.5)
  49 (24.5)
  38 (19.0)
Charlson’s score    2.86 (2.433)
Previous medication H2B
PPI
probiotics
  80 (42.8)
  67 (35.8)
  86 (46.0)
Previous antibiotics*
   No. of patients (%)/ 
      dosage(DDD)(SD)
ESC
Quinolones
Respiratory fluoroquinolone
Clindamycin
Metronidazole
BL/BLI
all-DDD
ABX-days
106 (56.7)/5.18 (7.306)
  90 (48.1)/5.86 (9.044)
  67 (35.8)/3.85 (7.170)
  42 (22.5)/1.88 (4.164)
  49 (26.2)/2.55 (6.048)
  61 (32.6)/3.37 (7.980)
 23.91 (19.847)
 18.6 (12.71)
Underlying condition Nasogastric tube
Recent operation
  53 (26.5)
  42 (21.0)
Severity score  
Older than 60
Fever > 38.3°C
Hypoalbuminemia
Leukocytosis
PMC
†
ICU admission
Severity score ≥ 2
 1.55 (1.337)
128 (64.0)
  25 (12.5)
15 (7.5)
  34 (17.0)
         31/65 (47.7)
  23 (11.5)
  75 (37.5)
CDI characters Stool-mucoid
Stool Fr > 10
Abdominal pain
Abdominal Td
  45 (22.5)
  35 (17.5)
  51 (25.5)
  67 (33.5)
Laboratory findings WBC
Albumin
CRP
        11060 (6601)
 3.2 (0.56)
 6.9 (6.51)
*The denominator for total CDI was 187 because patients whose medical record was 
not available were excluded; 
†The denominator comprised the patients who received 
endoscopic examination. CDI, Clostridium difficile infection; CVA, cerebrovascular ac-
cident; DM, diabetes mellitus; H2B, H2 blocker; PPI, proton-pump inhibitor; ESC, ex-
tended spectrum cephalosporin; BL/BLI, beta-lactam/beta-lactamase inhibitor; DDD, 
defined daily dose; ABX, antibiotics; PMC, pseudomembranous colitis; ICU, intensive 
care unit; Fr, frequency; Td, tenderness; WBC, white blood cell; CRP, C-reactive protein.
Table 4. Treatment outcome of Clostridium difficile infection according to antibiotics 
and number of episode
Treatment    
   choice
Treatment outcome
Number of episode
First  
episode
Recurrent 
episode
Total
Metronidazole Clinical response
   Cure
   Failure
   Mortality
      Attributable mortality
   Recurrence
   Global cure
109
91 (83.5)
12 (11.0)
6 (5.5)
0 (0.0)
20 (18.3)
75 (68.8)
14
12 (85.7)
1 (7.1)
1 (7.1)
0 (0.0)
  3 (21.4)
10 (71.4)
123
103 (83.7)
  13 (10.6)
  7 (5.7)
  0 (0.0)
  23 (18.7)
  85 (69.1)
Vancomycin Clinical response
   Cure
   Failure
   Mortality
      Attributable mortality
   Recurrence
   Global cure
9
  8 (88.9)
0 (0.0)
  1 (11.1)
0 (0.0)
  3 (33.3)
  5 (55.6)
8
  7 (87.5)
0 (0.0)
  1 (12.5)
  1 (12.5)
  4 (50.0)
  3 (37.5)
17
  15 (88.2)
  0 (0.0)
    2 (11.8)
  1 (5.9)
    7 (41.2)
    8 (47.1)
Total Clinical response
   Cure
   Failure
   Mortality
      Attributable mortality
   Recurrence
   Global cure
118
99 (83.9)
12 (10.2)
7 (5.9)
0 (0.0)
23 (19.5)
80 (67.8)
22
19 (86.4)
1 (4.5)
2 (9.1)
1 (4.5)
  7 (31.8)
13 (59.1)
140
118 (84.3)
13 (9.3)
  9 (6.4)
  1 (0.7)
  30 (21.4)
  93 (66.4)Kim J, et al.  •  Status of Clostridium difficile Infection in Korea
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CDI and 14.3% in severe cases (3, 19). Difference of study defi-
nition and retrospective methodology made results variable es-
pecially in incidence and relapse rate. By universal definition 
and prospective design of this study, these results could be com-
pared with other countries’ data and offered as baseline data.
  In this study, CDI accounted for 22.8% of AAD and overall in-
cidence of CDI was 71.6 per 100,000 patient days. The incidence 
of CDI in Korea (range, 52.5-114.0 cases per 100,000 patient-days) 
during 2009 was a little higher than that of the US (range, 3.0-7.1 
cases per 10,000 patient-days) before emergence of hyperviru-
lent strain (20). However, incidence of CDI in our hospital showed 
increasing tendency from November, 2009 and peaked at De-
cember, 2009 up to 2-fold higher than other months. To deter-
mine whether the incidence of CDI is increasing in our hospi-
tal, further observation is certainly necessary. Furthermore, con-
tribution of intra-hospital spread of the organisms to the increase 
of CDI in non-epidemiologic setting needs to be defined in our 
hospital where the principle of contact precaution for CDI is not 
adopted. 
  For the acquisition of CDI, the ratio of CO-CDI to HA-CDI di-
agnosed during the study period was 0.06 (11/189). In Canada, 
the US and Europe, the ratio of CO-CDI to HA-CDI ranged from 
0.23 to 0.59 (21). Although we did not actively search CO-CDI, 
the low proportion of CO-CDI compared with other countries 
suggests that there probably was few community-based out-
break or endemicity of CDI in community in Korea. 
  Previous studies demonstrated that approximately two-thirds 
of patients colonized with C. difficile become asymptomatic car-
rier (22), and asymptomatic carriage of C. difficile confers a low 
risk (approximately 1%) for subsequent CDAD, even in the pres-
ence of antibiotic therapy (23). In this study, toxigenic carrier 
was 10%, and 8% of them developed CDI after 60-207 days from 
the episode. Because stool culture was performed for the patients 
who have a loose stool with the use of antibiotics which did not 
meet the definition of diarrhea in our study, toxigenic carrier was 
far underestimated. For the subsequent development of CDI in 
toxigenic carrier, 8% is higher than expected according to the 
previous study (23). A recent report showed that 20% of patients 
with asymptomatic carriage of C. difficile developed CDI, and 
60% of them were epidemic NAP1 strains (22). The authors hy-
pothesized the reason for high incidence of CDI development 
in asymptomatic carriers as difference of virulence between ep-
idemic and non-epidemic strains. We suspected that toxigenic 
carrier in this study might be very mild CDI patients because 
25.7% of our CDI patient has a mild disease resolving spontane-
ously without medication. 
  Toxin profile of our strains was similar to the previous studies 
from Korea (24, 25). One study showed the increasing prevalence 
of A
-B
+CDT
- strains in the early 2000s, and the percent of the 
strains was 39.6% in 2004. In our data, A
-B
+CDT
-  strains showed 
15.4%, and those strains were identified from HA-CDI, CO-CDI 
and toxigenic carriers over the study period (data not shown). 
A
-B
+CDT
- strains are also prevalent in Japan or China; there were 
3.4%-5.6% of A
+B
+CDT
+ strains, 12.7%-22.3% of A
-B
+CDT
- strains, 
and 74.3%-81.7% of A
+B
+CDT
- strains between 1999 and 2008 
in Japan (26), and A
-B
+- strains comprised 33.3% in Shanghai 
(27). On the contrary, the prevalence of those strains in Europe, 
Canada or Australia was as low as 0%-6.3%, 2.4%, and 1.1%, re-
spectively (28, 29). High prevalence of A
-B
+- strains in Asia is an 
interesting finding, which might suggest the spread of the organ-
isms by common food transported internationally as well as heavy 
traffic of people among 3 countries. 
  Prior exposure to antibiotics varied in our study as expected. 
Use of clindamycin and the third generation cephalosporin was 
the most commonly associated with CDI (5), but exposure to 
antecedent fluoroquinolone has been a risk factor most prone 
to induce CDI recently (30). Increased fluoroquinolone usage 
and fluoroquinolone resistance of C. difficile strain had associ-
ated with epidemic spread of CDI caused by hypervirulent strain 
(1). In other study, the resistance rate to moxifloxacin of C. diffi-
cile was 42% (24). The MICs of fluoroquinolones were slightly 
higher for A
-B
+CDT
- strains than A
+B
+CDT
- strains (25). In this 
study, respiratory fluoroquinolone was the second most com-
mon antibiotics prescribed before CDI episode. Further obser-
vation for susceptibility of respiratory fluoroquinolone in C. dif-
ficile isolates is mandatory.
  Recurrence rates after treatment with metronidazole or van-
comycin are similar (1). In this study, recurrence rate of vanco-
mycin was higher than metronidazole (41.2% vs 18.7%, P = 0.054). 
Our hospital strategy for treatment of CDI was that vancomycin 
is superior to metronidazole as the first-line agent for patients 
with severe CDI according to previous studies (1, 9). Severe CDIs 
were more included in vancomycin treated group than metro-
nidazole treated group (52.9% vs 21.1%, P = 0.009). For the com-
parison of recurrence rate between treatments, multivariate 
analysis was done and there was no significance in statistic (OR, 
2.656; 95% CI, 0.86-8.208; P = 0.09) (data not shown). 
  In this study, recurrence rate after vancomycin and metroni-
dazole treatment were 41.2% and 18.7%, respectively. CDI sever-
ity score was different statistically between vancomycin treated 
group and metronidazole treated group (2.71 ± 1.532 vs 1.62 ±  
1.277, P = 0.002). Severe CDIs were more included in vancomy-
cin treated group than metronidazole treated group (52.9% vs 
21.1%, P = 0.009). For the comparison of clinical outcome be-
tween treatments, severity score should be adjusted before anal-
ysis. Multivariate analysis was done to adjust severity score in 
recurrence rate according to treatment and there was no signif-
icance of treatment in statistic (OR, 2.656; 95% CI, 0.86-8.208; 
P = 0.09) (data not shown).
  In conclusion, the incidence of CDI in Korea is 71.6 per 100,000 
patient days, a little higher than other reports during the non-
epidemic setting. Incidence and clinical severity as well as toxin Kim J, et al.  •  Status of Clostridium difficile Infection in Korea
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type indicate no evidence of outbreak by hypervirulent BI/NAP1/ 
027 strain in Korea. We expect that the change of epidemiology 
and clinical severity in CDI can be evaluated based on these re-
sults. Continued research into the epidemiology and disease 
severity is mandatory. 
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AUTHOR SUMMARY
Epidemiology and Clinical Characteristics of Clostridium difficile Infection in 
a Korean Tertiary Hospital
Jieun Kim, Hyunjoo Pai, Mi-ran Seo and Jung Oak Kang
The incidence, morbidity, and mortality of Clostridium difficile infection (CDI) are increasing since the recognition of hypervirulent 
strain. As a baseline data for monitoring of epidemiology and disease pattern we designed this study. The mean incidence of CDI 
per 100,000 patient-days was 71.6 by month, and 37.5% of CDI was severe cases. Among treated patients, 84.3% achieved 
clinical cure and attributed mortality was 0.7%. Recurrence rate was 21.4% and cure without recurrence was 66.4%. The most 
common type of toxin was toxin A-positive/toxin B-positive strain (77.5%) and toxin A-negative/toxin B-positive strains (15.4%). 
We expect the change of epidemiology and clinical severity in Korea, which require continuous observation.